Analysis of a National Programme for Selective Internal Radiation Therapy for Colorectal Cancer Liver Metastases
Slevin, Nicholas J
AffiliationCedar, Cardiff & Vale University Health Board, Cardiff Medicentre, Cardiff, UK
MetadataShow full item record
AbstractAIMS: Patients with chemotherapy-refractory colorectal cancer liver metastases have limited therapeutic options. Selective internal radiation therapy (SIRT) delivers yttrium 90 microspheres as a minimally invasive procedure. This prospective, single-arm, observational, service-evaluation study was part of National Health Service England Commissioning through Evaluation. METHODS: Patients eligible for treatment had histologically confirmed carcinoma with liver-only/liver-dominant metastases with clinical progression during or following oxaliplatin-based and irinotecan-based chemotherapy. All patients received SIRT plus standard of care. The primary outcome was overall survival; secondary outcomes included safety, progression-free survival (PFS) and liver-specific PFS (LPFS). RESULTS: Between December 2013 and March 2017, 399 patients were treated in 10 centres with a median follow-up of 14.3 months (95% confidence interval 9.2-19.4). The median overall survival was 7.6 months (95% confidence interval 6.9-8.3). The median PFS and LPFS were 3.0 months (95% confidence interval 2.8-3.1) and 3.7 months (95% confidence interval 3.2-4.3), respectively. During the follow-up period, 143 patients experienced an adverse event and 8% of the events were grade 3. CONCLUSION: Survival estimates from this pragmatic study show clinical outcomes attainable in the National Health Service comparable with previously published data. This study shows the value of a registry-based commissioning model to aid national commissioning decisions for highly specialist cancer treatments.
CitationWhite J, Carolan-Rees G, Dale M, Morgan HE, Patrick HE, See TC, et al. Analysis of a National Programme for Selective Internal Radiation Therapy for Colorectal Cancer Liver Metastases. Clinical Oncology. 2018 Oct.
JournalClin Oncol (R Coll Radiol )
- Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy.
- Authors: Sofocleous CT, Garcia AR, Pandit-Taskar N, Do KG, Brody LA, Petre EN, Capanu M, Longing AP, Chou JF, Carrasquillo JA, Kemeny NE
- Issue date: 2014 Mar
- FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer.
- Authors: Dutton SJ, Kenealy N, Love SB, Wasan HS, Sharma RA, FOXFIRE Protocol Development Group and the NCRI Colorectal Clinical Study Group.
- Issue date: 2014 Jul 9
- Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study.
- Authors: Gibbs P, Gebski V, Van Buskirk M, Thurston K, Cade DN, Van Hazel GA, SIRFLOX Study Group.
- Issue date: 2014 Dec 1
- Selective internal radiation therapy for liver metastases from colorectal cancer.
- Authors: Townsend AR, Chong LC, Karapetis C, Price TJ
- Issue date: 2016 Nov
- Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma.
- Authors: Gibbs P, Do C, Lipton L, Cade DN, Tapner MJ, Price D, Bower GD, Dowling R, Lichtenstein M, van Hazel GA
- Issue date: 2015 Oct 26